Isotocyanazene

Isotocyanazene
Identifiers
  • 1-[2-(diethylamino)ethyl]-2-[(4-prop-2-yloxyphenyl)methyl]benzimidazole-5-carbonitrile
Chemical and physical data
FormulaC24H30N4O
Molar mass390.531 g·mol−1
3D model (JSmol)
  • CC(C)Oc1ccc(cc1)Cc1nc2cc(ccc2n1CCN(CC)CC)C#N

Isotocyanazene (Isotonitazene 5-cyano analogue) is a benzimidazole derivative which has been sold as a designer drug, first reported in the United Kingdom in 2025, and is presumed to have opioid effects.[1]

See also

References

  1. ^ McHenry RD, Dunlop LC, Hudson S, Walters M, Dear JW, Lowe DJ (July 2025). "Isotocyanozene: detection of the 5-cyano analog of isotonitazene in human biological samples". Clinical Toxicology. Philadelphia, Pa.: 1–2. doi:10.1080/15563650.2025.2528990. PMID 40625206.



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.